Amyloid imaging in aging and dementia: testing the amyloid hypothesis in vivo - PubMed (original) (raw)
Review
Amyloid imaging in aging and dementia: testing the amyloid hypothesis in vivo
G D Rabinovici et al. Behav Neurol. 2009.
Abstract
Amyloid imaging represents a major advance in neuroscience, enabling the detection and quantification of pathologic protein aggregations in the brain. In this review we survey current amyloid imaging techniques, focusing on positron emission tomography (PET) with (11)carbon-labelled Pittsburgh Compound-B ((11)C-PIB), the most extensively studied and best validated tracer. PIB binds specifically to fibrillar beta-amyloid (Abeta) deposits, and is a sensitive marker for Abeta pathology in cognitively normal older individuals and patients with mild cognitive impairment (MCI) and Alzheimer's disease (AD). PIB-PET provides us with a powerful tool to examine in vivo the relationship between amyloid deposition, clinical symptoms, and structural and functional brain changes in the continuum between normal aging and AD. Amyloid imaging studies support a model in which amyloid deposition is an early event on the path to dementia, beginning insidiously in cognitively normal individuals, and accompanied by subtle cognitive decline and functional and structural brain changes suggestive of incipient AD. As patients progress to dementia, clinical decline and neurodegeneration accelerate and proceed independently of amyloid accumulation. In the future, amyloid imaging is likely to supplement clinical evaluation in selecting patients for anti-amyloid therapies, while MRI and FDG-PET may be more appropriate markers of clinical progression.
Similar articles
- PET imaging of brain amyloid in dementia: a review.
Quigley H, Colloby SJ, O'Brien JT. Quigley H, et al. Int J Geriatr Psychiatry. 2011 Oct;26(10):991-9. doi: 10.1002/gps.2640. Epub 2010 Dec 28. Int J Geriatr Psychiatry. 2011. PMID: 21905095 Review. - Long night's journey into the day: amyloid-β imaging in Alzheimer's disease.
Villemagne VL, Rowe CC. Villemagne VL, et al. J Alzheimers Dis. 2013;33 Suppl 1:S349-59. doi: 10.3233/JAD-2012-129034. J Alzheimers Dis. 2013. PMID: 22710919 Review. - Amyloid-β and cognition in aging and Alzheimer's disease: molecular and neurophysiological mechanisms.
Hampel H. Hampel H. J Alzheimers Dis. 2013;33 Suppl 1:S79-86. doi: 10.3233/JAD-2012-129003. J Alzheimers Dis. 2013. PMID: 22531423 Review. - In vivo detection of microstructural correlates of brain pathology in preclinical and early Alzheimer Disease with magnetic resonance imaging.
Zhao Y, Raichle ME, Wen J, Benzinger TL, Fagan AM, Hassenstab J, Vlassenko AG, Luo J, Cairns NJ, Christensen JJ, Morris JC, Yablonskiy DA. Zhao Y, et al. Neuroimage. 2017 Mar 1;148:296-304. doi: 10.1016/j.neuroimage.2016.12.026. Epub 2016 Dec 15. Neuroimage. 2017. PMID: 27989773 Free PMC article. - Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease.
Jack CR Jr, Lowe VJ, Weigand SD, Wiste HJ, Senjem ML, Knopman DS, Shiung MM, Gunter JL, Boeve BF, Kemp BJ, Weiner M, Petersen RC; Alzheimer's Disease Neuroimaging Initiative. Jack CR Jr, et al. Brain. 2009 May;132(Pt 5):1355-65. doi: 10.1093/brain/awp062. Epub 2009 Mar 31. Brain. 2009. PMID: 19339253 Free PMC article.
Cited by
- [11C]PIB amyloid quantification: effect of reference region selection.
Heeman F, Hendriks J, Lopes Alves I, Ossenkoppele R, Tolboom N, van Berckel BNM, Lammertsma AA, Yaqub M; AMYPAD Consortium. Heeman F, et al. EJNMMI Res. 2020 Oct 19;10(1):123. doi: 10.1186/s13550-020-00714-1. EJNMMI Res. 2020. PMID: 33074395 Free PMC article. - Positron emission tomography imaging in neurological disorders.
Politis M, Piccini P. Politis M, et al. J Neurol. 2012 Sep;259(9):1769-80. doi: 10.1007/s00415-012-6428-3. J Neurol. 2012. PMID: 22297461 Review. - Chemical Biology, Molecular Mechanism and Clinical Perspective of γ-Secretase Modulators in Alzheimer's Disease.
Bulic B, Ness J, Hahn S, Rennhack A, Jumpertz T, Weggen S. Bulic B, et al. Curr Neuropharmacol. 2011 Dec;9(4):598-622. doi: 10.2174/157015911798376352. Curr Neuropharmacol. 2011. PMID: 22798753 Free PMC article. - Bapineuzumab.
Kerchner GA, Boxer AL. Kerchner GA, et al. Expert Opin Biol Ther. 2010 Jul;10(7):1121-30. doi: 10.1517/14712598.2010.493872. Expert Opin Biol Ther. 2010. PMID: 20497044 Free PMC article. Review. - Clinical aspects of melatonin intervention in Alzheimer's disease progression.
Cardinali DP, Furio AM, Brusco LI. Cardinali DP, et al. Curr Neuropharmacol. 2010 Sep;8(3):218-27. doi: 10.2174/157015910792246209. Curr Neuropharmacol. 2010. PMID: 21358972 Free PMC article.
References
- Brain. 2008 Mar;131(Pt 3):665-80 - PubMed
- Proc Natl Acad Sci U S A. 2008 Mar 18;105(11):4441-6 - PubMed
- Arch Neurol. 2008 Apr;65(4):540-4 - PubMed
- Neuropsychologia. 2008;46(6):1688-97 - PubMed
- Neuropsychologia. 2008;46(6):1636-41 - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- K23 AG031861-01A1/AG/NIA NIH HHS/United States
- P01 AG019724-03/AG/NIA NIH HHS/United States
- P01 AG019724/AG/NIA NIH HHS/United States
- 50-AG023501/AG/NIA NIH HHS/United States
- P50 AG023501-01/AG/NIA NIH HHS/United States
- K23-AG031861/AG/NIA NIH HHS/United States
- R01 AG034570/AG/NIA NIH HHS/United States
- P50 AG023501/AG/NIA NIH HHS/United States
- R01 AG027859-01A1/AG/NIA NIH HHS/United States
- R01 AG027859/AG/NIA NIH HHS/United States
- P01-AG1972403/AG/NIA NIH HHS/United States
- K23 AG031861/AG/NIA NIH HHS/United States
- AG027859/AG/NIA NIH HHS/United States
LinkOut - more resources
Full Text Sources
Medical
Research Materials